公开(公告)号：EP4431528A1

公开(公告)日：2024-09-18

申请号：EP21961862.6

申请日：2021-10-29

申请人： Longbio Pharma (Suzhou) Co., Ltd.

发明人： SUN, Nai-Chau ,  SUN, Chow-Rou-Yun ,  MA, Haili ,  LIU, Yunhua ,  YANG, Hongzhou ,  GUO, Ruowen ,  GAO, Qi ,  LIU, Heng

IPC分类号： C07K16/42 ,  C07K16/28 ,  C12N15/63 ,  A61P37/08 ,  A61K47/18 ,  A61K39/395 ,  A61K39/00 ,  A61P11/06

CPC分类号： A61K39/00 ,  A61K39/395 ,  A61K47/18 ,  A61P11/06 ,  A61P37/08 ,  C07K16/28 ,  C07K16/42 ,  C12N15/63

摘要： The present application relates to an antigen binding protein comprising at least one CDR of a heavy chain variable region and at least one CDR of a light chain variable region, wherein said heavy chain variable region comprises an amino acid sequence as set forth in any one of SEQ ID NOs: 73 or 74, and the light chain variable region comprises an amino acid sequence as set forth in any one of SEQ ID NOs: 75 or 76.

公开(公告)号：EP4414484A2

公开(公告)日：2024-08-14

申请号：EP24170934.4

申请日：2017-02-03

申请人： Trianni, Inc.

发明人： KILLEEN, Nigel ,  HASENHINDL, Christoph ,  DUONG, Bao

IPC分类号： C40B40/10

CPC分类号： A01K67/0278 ,  C07K16/42 ,  A01K2217/07220130101 ,  C07K16/00 ,  C12N5/0635 ,  C12N5/12 ,  C07K2317/62220130101 ,  A01K2267/0120130101 ,  A01K2227/10520130101 ,  C12N2510/0220130101 ,  C12N5/16 ,  C07K14/31 ,  C07K2319/0020130101 ,  C07K2319/0220130101 ,  C07K2319/0320130101

摘要： The present invention provides methods and compositions for generating transgenic animals, including transgenic mammals, as well as plasma cells that allow for cell surface capture of secreted immunoglobulin molecules produced endogenously in the plasma cells.

公开(公告)号：EP4350345A3

公开(公告)日：2024-07-24

申请号：EP23214392.5

申请日：2012-06-25

申请人： Ablynx N.V.

发明人： Baumeister, Judith ,  Bouche, Marie-Paule Lucienne Armanda ,  Boutton, Carlo ,  Buyse, Marie-Ange ,  Snoeck, Veerle ,  Staelens, Stephanie

IPC分类号： C07K16/00 ,  G01N33/00 ,  C07K16/28 ,  C07K16/42

CPC分类号： A61K2039/50520130101 ,  C07K16/00 ,  C07K16/2875 ,  C07K16/42 ,  C07K2317/2220130101 ,  C07K2317/3120130101 ,  C07K2317/3420130101 ,  C07K2317/3520130101 ,  C07K2317/56720130101 ,  C07K2317/56920130101 ,  C07K2317/9220130101 ,  G01N33/5306 ,  G01N33/54393 ,  G01N33/6857 ,  C07K16/08 ,  C12N5/0688

摘要： This invention provides, and in certain specific but non-limiting aspects relates to: assays that can be used to predict whether a given ISV will be subject to protein interference as described herein and/or give rise to an (aspecific) signal in such an assay (such as for example in an ADA immunoassay). Such predictive assays could for example be used to test whether a given ISV could have a tendency to give rise to such protein interference and/or such a signal; to select ISV's that are not or less prone to such protein interference or giving such a signal; as an assay or test that can be used to test whether certain modification(s) to an ISV will (fully or partially) reduce its tendency to give rise to such interference or such a signal; and/or as an assay or test that can be used to guide modification or improvement of an ISV so as to reduce its tendency to give rise to such protein interference or signal; - methods for modifying and/or improving ISV's to as to remove or reduce their tendency to give rise to such protein interference or such a signal; - modifications that can be introduced into an ISV that remove or reduce its tendency to give rise to such protein interference or such a signal; ISV's that have been specifically selected (for example, using the assay(s) described herein) to have no or low(er)/reduced tendency to give rise to such protein interference or such a signal; modified and/or improved ISV's that have nor or a low(er)/reduced tendency to give rise to such protein interference or such a signal.

公开(公告)号：EP3411476B1

公开(公告)日：2024-04-24

申请号：EP17748280.9

申请日：2017-02-03

IPC分类号： C07K14/31 ,  C07K16/00 ,  C07K16/42 ,  C07K19/00 ,  C12N5/0781 ,  C12N5/10 ,  C12N5/12 ,  C12N5/16 ,  A61K35/17 ,  A61K39/395 ,  A61K47/62 ,  A61K47/65 ,  A01K67/027 ,  C40B40/06 ,  C40B40/08 ,  C40B40/10

CPC分类号： A01K67/0278 ,  C07K16/42 ,  A01K2217/07220130101 ,  C07K16/00 ,  C12N5/0635 ,  C12N5/12 ,  C07K2317/62220130101 ,  A01K2267/0120130101 ,  A01K2227/10520130101 ,  C12N2510/0220130101 ,  C12N5/16 ,  C07K14/31 ,  C07K2319/0020130101 ,  C07K2319/0220130101 ,  C07K2319/0320130101

公开(公告)号：EP3411476A1

公开(公告)日：2018-12-12

申请号：EP17748280.9

申请日：2017-02-03

申请人： Trianni, Inc.

发明人： KILLEEN, Nigel ,  HASENHINDL, Christoph ,  DUONG, Bao

IPC分类号： C12N5/10 ,  A61K35/17 ,  A61K47/62 ,  A61K47/65 ,  A61K39/395 ,  C12Q1/68 ,  C40B40/06 ,  C40B40/08 ,  C40B40/10

CPC分类号： C07K14/315 ,  A01K67/0278 ,  A01K2217/072 ,  A01K2227/105 ,  A01K2267/01 ,  C07K14/70503 ,  C07K14/70514 ,  C07K14/70539 ,  C07K14/70596 ,  C07K16/00 ,  C07K16/42 ,  C07K2317/14 ,  C07K2317/622 ,  C07K2319/02 ,  C07K2319/03 ,  C12N5/0635 ,  C12N5/12 ,  C12N2510/02

摘要： The present invention provides methods and compositions for generating transgenic animals, including transgenic mammals, as well as plasma cells that allow for cell surface capture of secreted immunoglobulin molecules produced endogenously in the plasma cells.

公开(公告)号：EP3333193A1

公开(公告)日：2018-06-13

申请号：EP17203491.0

申请日：2012-02-29

申请人： Roche Glycart AG

发明人： HOFER, Thomas U. ,  HOSSE, Ralf ,  MOESSNER, Ekkehard ,  UMANA, Pablo

IPC分类号： C07K16/30

CPC分类号： C07K16/42 ,  A61K39/39566 ,  A61K45/06 ,  A61K2039/505 ,  A61N5/10 ,  C07K16/3007 ,  C07K2317/24 ,  C07K2317/41 ,  C07K2317/565 ,  C07K2317/732 ,  C07K2317/92 ,  C07K2317/94

摘要： The present invention provides antigen binding molecules (ABMs) which bind membrane-bound CEA, including ABMs with improved therapeutic properties, and methods of using the same.

公开(公告)号：EP3313417A1

公开(公告)日：2018-05-02

申请号：EP16815332.8

申请日：2016-06-23

申请人： Bioverativ USA Inc.

发明人： PARRY, Graham ,  NIKITIN, Pavel A. ,  PANICKER, Sandip

IPC分类号： A61K35/14 ,  A61K35/15 ,  A61K39/395

CPC分类号： A61K39/39566 ,  A61K35/15 ,  A61K39/395 ,  A61K39/39541 ,  A61K2039/505 ,  C07K16/40 ,  C07K16/42 ,  C07K2317/24 ,  C07K2317/567 ,  C07K2317/76

摘要： The present disclosure provides methods of treating an alloimmune or autoimmune disorder in an individual; the methods involve administering to the individual an effective amount of an antibody specific for complement component C1s. The present disclosure provides a method of monitoring the efficacy of a subject treatment method; the method involves detecting the level of autoantibody or alloantibody in a biological sample obtained from the individual.

公开(公告)号：EP3266800A1

公开(公告)日：2018-01-10

申请号：EP17184307.1

申请日：2012-01-31

申请人： BAC IP B.V.

发明人： Hermans, Wilhelmus Josephus Johanna ,  Blokland, Sven ,  van Kesteren, Maria Anna ,  Horrevoets, Johanna Magaretha ,  Detmers, Franciscus Johan Marinus

IPC分类号： C07K16/42 ,  C07K16/06 ,  C07K1/22

CPC分类号： C07K16/4241 ,  C07K1/22 ,  C07K16/065 ,  C07K16/42 ,  C07K16/4283 ,  C07K2317/22 ,  C07K2317/33 ,  C07K2317/34 ,  C07K2317/522 ,  C07K2317/569

摘要： The present disclosure relates to a method for the purification of a human IgG-CH1 domain comprising molecule using an antigen-binding protein that is capable of binding to an epitope that is comprised in the CH1 domain of each of human IgG1, human IgG2, human IgG3 and human IgG4. The disclosure further relates to the antigen-binding proteins that can be used in the method of the disclosure. The frame-work regions of the antigen-binding proteins of the disclosure preferably correspond to those of antibodies naturally that are devoid of light chains as may e.g. be found in camelids. The disclosure further relates to nucleic acids that encode such antigen-binding proteins, to immunoadsorbent materials that comprise such proteins, and to the uses of such immunoadsorbent materials for the purification of IgG-CH1 domain containing molecules from a variety of species.

摘要翻译： 本公开内容涉及使用抗原结合蛋白来纯化包含分子的人IgG-CH1结构域的方法，所述抗原结合蛋白能够结合包含在人IgG1，人IgG2，人类的每一个的CH1结构域中的表位 IgG3和人IgG4。 本公开还涉及可用于本公开方法中的抗原结合蛋白。 本公开的抗原结合蛋白的框架区优选对应于天然抗体的框架区，所述天然抗体不含轻链， 被发现在camelids。 本公开还涉及编码此类抗原结合蛋白的核酸，涉及包含此类蛋白的免疫吸附材料，并涉及此类免疫吸附材料用于纯化来自多种物种的含IgG-CH1结构域的分子的用途。

公开(公告)号：EP1877101B1

公开(公告)日：2016-11-16

申请号：EP06758689.1

申请日：2006-04-27

申请人： Ventana Medical Systems, Inc.

发明人： BIENIARZ, Christopher ,  WONG, Jennifer ,  LEFEVER, Mark ,  KOSMEDER, Jerome W. ,  ASHWORTH-SHARPE, Julia ,  KERNAG, Casey, A.

IPC分类号： A61K47/48 ,  G01N33/535 ,  G01N33/58

CPC分类号： G01N33/535 ,  A61K47/65 ,  A61K47/6815 ,  C07K16/42 ,  C07K16/44 ,  C07K2317/76 ,  C12N9/0065 ,  C12N9/16 ,  C12N9/96

公开(公告)号：EP2987806A3

公开(公告)日：2016-07-13

申请号：EP15180982.9

申请日：2012-08-13

申请人： Glaxo Group Limited

发明人： ASHMAN, Claire ,  BIRCHLER, Mary ,  DE WILDT, Rudolf M.T. ,  HOLLAND, Claire ,  LEWIS, Alan Peter ,  MORLEY, Peter ,  SANDAL, Thomas ,  STEWARD, Michael

IPC分类号： C07K16/00 ,  C07K16/22 ,  C07K16/28 ,  C07K16/42

CPC分类号： C07K16/42 ,  C07K16/00 ,  C07K16/22 ,  C07K16/2878 ,  C07K2317/40 ,  C07K2317/567 ,  C07K2317/569 ,  C07K2317/60 ,  C07K2317/64 ,  C07K2319/00

摘要： The present invention relates to modified proteins and peptides that have reduced ability to bind to pre-existing antibodies. Such modified protein/peptide molecules can comprise C-terminal additions, extensions or tags and/or certain amino acid substitutions. Such modified molecules (including fusions and conjugates thereof) comprise proteins, peptides, antigen binding molecules, antibodies or antibody fragments such as single variable domains e.g. human immunoglobulin (antibody) single variable domains, and also single variable domains derived from non-human sources such as a llama or camel, e.g. a VHH including a Nanobody™ (described in e.g. WO 94/04678 and WO 95/04079 inter alia). The invention further relates to uses, formulations, compositions comprising such modified C-terminally extended and/or amino acid substituted molecules and also to methods of production and expression of these molecules.